臨床検査54巻3号

2010年03月発行

今月の主題 骨髄増殖性疾患 各論 〈治療―治療方針・治療成績・予後〉

本態性血小板血症

著者： 田丸智巳¹² 西川政勝²

所属機関： ¹三重大学医学部附属病院臨床研究開発センター ²三重大学医学部臨床創薬研究学

ページ範囲：P.287 - P.292

　本態性血小板血症は骨髄増殖性新生物の中では比較的予後良好な疾患であり，その合併症である血栓症・出血の管理が最も重要である．リスク因子として年齢60歳以上，血栓症・出血の既往，血小板数150万/μl以上が挙げられ，リスクに応じた治療を行う．治療として経過観察，抗血小板療法(アスピリン)，血小板減少療法(ヒドロキシウレアなど)，時に血小板吸着療法などが行われる．妊娠希望者および妊婦に対しては早期から産婦人科医との連携を綿密に行い，リスクを考慮しアスピリンや低分子ヘパリン，インターフェロンなどの治療を行う．

参考文献

1) 田丸智巳，西川政勝：本態性血小板血症に対する治療法は？　EBM血液疾患の治療2008-2009(押見和夫，別所正美，岡本真一郎，他編)，中外医学社，pp539-544, 2007

2) 田丸智巳，西川政勝：本態性血小板血症：治療．最新医学別冊新しい診断と治療のABC63血小板減少症・増多症(池田康夫編)，最新医学社，pp65-73, 2009

3) Barbui T, Barosi G, Grossi A, et al：Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica　89：215-232, 2004

4) Harrison CN, Campbell PJ, Buck G, et al：Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med　353：33-45, 2005

5) Cortelazzo S, Viero P, Finazzi G, et al：Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol　8：556-562, 1990

6) Budde U, Schaefer G, Mueller N, et al：Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood　64：981-985, 1984

7) Birgegård G：Long-term management of thrombocytosis in essential thrombocythaemia. Ann Hematol　88：1-10, 2009

8) Finazzi G, Barbui T：Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia　22：1494-1502, 2008

9) Harrison CN, Green AR：Essential thrombocythaemia. Best Pract Res Clin Haematol　19：439-453, 2006

10) Tefferi A：Essential thrombocythemia, polycythemia vera, and myelofibrosis：current management and the prospect of targeted therapy. Am J Hematol　83：491-497, 2008

11) Cortelazzo S, Finazzi G, Ruggeri M, et al：Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med　332：1132-1136, 1995

12) van Genderen PJ, Mulder PG, Waleboer M, et al：Prevention and treatment of thrombotic complications in essential thrombocythaemia：efficacy and safety of aspirin. Br J Haematol　97：179-184, 1997

13) Landolfi R, Marchioli R, Kutti J, et al：Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med　350：114-124, 2004

14) Finazzi G, Ruggeri M, Rodeghiero F, et al：Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea：long-term follow-up of a randomized clinical trial. Br J Haematol　110：577-583, 2000

15) Langer C, Lengfelder E, Thiele J, et al：Pegylated interferon for the treatment of high risk essential thrombocythemia：results of a phase II study. Haematologica　90：1333-1338, 2005

16) Samuelsson J, Hasselbalch H, Bruserud O, et al：A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia：feasibility, clinical and biologic effects, and impact on quality of life. Cancer　106：2397-2405, 2006

17) Dan K, Yamada T, Kimura Y, et al：Clinical features of polycythemia vera and essential thrombocythemia in Japan：retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group. Int J Hematol　83：443-449, 2006

18) Landgren O, Goldin LR, Kristinsson SY, et al：Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24, 577 first-degree relatives of 11, 039 patients with myeloproliferative neoplasms in Sweden. Blood　112：2199-2204, 2008

19) Melillo L, Tieghi A, Candoni A, et al：Outcome of 122 pregnancies in essential thrombocythemia patients：A report from the Italian registry. Am J Hematol　84：636-640, 2009

20) 鈴木恵子，下田和哉：本態性血小板血症患者の妊娠と管理．血液・腫瘍科　55：399-407, 2007

21) Passamonti F, Randi ML, Rumi E, et al：Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2(617V＞F)mutation. Blood　110：485-489, 2007

22) Griesshammer M, Struve S, Barbui T：Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Rev　22：235-245, 2008

23) Liebelt EL, Balk SJ, Faber W, et al：NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. Birth Defects Res B Dev Reprod Toxicol　80：259-366, 2007

24) Tefferi A, Passamonti F：Essential thrombocythemia and pregnancy：Observations from recent studies and management recommendations. Am J Hematol　84：629-630, 2009